AstraZeneca COVID-19 vaccine
ChAdOx1 nCoV-19 is the name of a viral vector COVID-19 vaccine product more commonly referred to as the Oxford-AstraZeneca vaccine, or in colloquial terms, simply the AstraZeneca vaccine.
History
Development
In June 2020, the Bill & Melinda Gates Foundation contributed $750 million to the development of the vaccine candidate.1)
Distribution
On April 14, 2021, the Danish Health Authority announced it would stop administering the AstraZeneca-Oxford vaccine “because of its possible link to rare cases of blood clotting” and the “fact that the COVID-19 epidemic in Denmark is currently under control and other vaccines are available.”2)
On April 23, 2021, Canada's National Advisory Committee on Immunization (NACI) recommended the AstraZeneca-Oxford vaccine be offered to “all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots.”3)
1)
Canellis, D. (2020, June 5). Bill Gates commits $750M to help Oxford vaccinate the world against COVID-19. TNW | Fintech-Ecommerce. http://archive.today/2023.02.25-123239/https://thenextweb.com/news/bill-gates-covid-coronavirus-vaccine-750-million-oxford-azd1222
2)
Treisman, R. (2021, April 14). Denmark Drops AstraZeneca Vaccine, Citing Rare Side Effects, Epidemic “Under Control.” NPR. http://archive.today/2021.04.21-192633/https://www.npr.org/sections/coronavirus-live-updates/2021/04/14/987166681/denmark-drops-astrazeneca-vaccine-citing-rare-side-effects-epidemic-under-contro
3)
Pelley, L. (2021, April 23). Canadians over 30 should be offered AstraZeneca-Oxford COVID-19 vaccine, advisory body recommends. CBC News. http://archive.today/2021.04.24-073245/https://www.cbc.ca/news/health/astrazeneca-covid-19-vaccine-over-30-naci-1.6000052